Amarillo Biosciences Teams With Bio-Stasis International to Launch Dietary Supplement Virapress

Tue Jul 19, 2011 11:15am EDT

  AMARILLO, TX, Jul 19 (MARKET WIRE) -- 
Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced that it
has formed an alliance with Bio-Stasis International, Inc., a dietary
supplement internet marketer, to launch Bio-Stasis International's
Virapress. Bio-Stasis plans to embark on an extensive internet marketing
program for Virapress on August 1, 2011, targeting alternative and
complimentary medical practitioners. 

    Virapress is a dietary supplement derived from a bovine protein extract
produced by ABI and will be marketed with claims to improve health and
enhance immunity. In parallel with Bio-Stasis International's internet
marketing campaign, ABI will market its bovine extract to health food
stores and internationally under ABI's brand name. ABI has already
received serious inquiries about distribution rights from marketers in 9
different countries in the Middle East and Africa and has commenced
negotiations on international distribution rights.

    "We expect our internet marketing campaign to significantly increase the
market for Virapress and, also, its primary ingredient, bovine extract,"
said Lawrence H. Griffin, president, Bio-Stasis International.

    Virapress has not been evaluated by the Food and Drug Administration, and
should not take the place of a regular medical evaluation by a licensed
health practitioner. 

    About Bio-Stasis International, Inc.

    Bio-Stasis is committed to the promotion of natural products which have
been shown to promote health and healing. Each Bio-Stasis product must
have scientific evidence to support effectiveness, without side effects.
For additional information, please visit the Bio-Stasis International
Inc.'s website www.virapress.com 

    About Amarillo Biosciences
 Amarillo Biosciences, Inc. is a U.S.
biotechnology firm operating in global partnership with the Hayashibara
Group, which also holds 6% of Amarillo Biosciences shares and has
provided over $18 million in loans, grants and equity investments. The
Company's primary focus is extensive and ongoing R&D into the use of
low-dose, orally administered interferon as a treatment for a variety of
conditions, including influenza, hepatitis C, chronic cough, and
opportunistic infections in patients who are HIV positive. The Company
has invested nearly $40 million to establish oral interferon as a
therapeutic agent. The majority of those funds were invested in clinical
trials in an effort to achieve FDA approval for interferon. Additional
information is available on the web at http://www.amarbio.com/.

    Except for the historical information contained herein, the matters
discussed in this news release are forward-looking statements that
involve risks and uncertainties, including uncertainties related to
product development, uncertainties related to the need for regulatory and
other government approvals, dependence on proprietary technology,
uncertainty of market acceptance of oral interferon or the Company's
other product candidates and other risks detailed from time to time in
the Company's filings with the Securities and Exchange Commission. In
particular, see "Item 1. Description of Business" and "Item 7A.
Qualitative and Quantitative Disclosures About Market Risk" of the
Company's Form 10-K for the fiscal year ended December 31, 2010. 

    

Investor Relations: 
Philippe Niemetz 
PAN Consultants, Ltd. 
e-mail: p.niemetz@panconsultants.com
Tel: 800-477-7570; 212-344-6464
Fax: 212-618-1276

Investor Inquiries: 
Josh Tyrell
Interactive Business Alliance, LLC
e-mail: jtyrell@ibaconsultingllc.com 
Tel: 866-525-4714 

Copyright 2011, Market Wire, All rights reserved.

-0-
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.